Proposed Nodal Cancer Index (NCI) in ovarian carcinomatosis.

IF 2.1 Q3 ONCOLOGY
M D Ray, Manish Kumar Gaur
{"title":"Proposed Nodal Cancer Index (NCI) in ovarian carcinomatosis.","authors":"M D Ray, Manish Kumar Gaur","doi":"10.1186/s43046-025-00256-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The nodal positivity in advanced ovarian cancers is approximately 68-70% histopathologically. Even after neoadjuvant chemotherapy (NACT) chance of nodal positivity is around 50-80%. In the prevailing literature, the nodal burden is a neglected entity in both assessment and documentation and complete clearance during the CRS. We aim to highlight the importance of nodal dissection and propose a Nodal Cancer Index (NCI) like PCI for ovarian cancers based on our experience of 105 cases.</p><p><strong>Materials and methods: </strong>We included 105 patients with advanced ovarian cancers who underwent CRS. Retroperitoneal lymph nodes and bilateral pelvic lymph node dissection were routinely done in all the cases. For Nodal Cancer Index calculation, the abdomen is divided into 13 zones, zones 1-6 for retroperitoneum, zones 1-6 for Pelvic nodes, and zone 0 for extra-abdominal nodes. Furthermore, a Nodal size score ranging from 1 to 3 has been proposed so that the Nodal Cancer Index ranges from 13 to 39.</p><p><strong>Results: </strong>The median age of the patients was 51 years (range 19-71) and the most significant patients were in stage III (65.7%), and 34.3% had stage IV disease at presentation. The lymph nodes were found to be positive in 62 patients (59%), and the positivity rate was higher in patients who underwent upfront surgery 36 (58.1%) as compared to 26 (41.9%) in those who received NACT. The majority of the patients (56.6%) had positive lymph nodes in both the pelvic and retroperitoneal groups, whereas 19.3% had only pelvic nodes positive, and 24.2% had only retroperitoneal nodes positive. The probability of overall survival at 5 years in our patients was 48.9% (95% CI = 35.5-61).</p><p><strong>Conclusion: </strong>The results of our analytic observation confirm that systemic lymphadenectomy of all 13 zones proposed by our study should be an integral part of optimal CRS in the advanced carcinoma ovary and this will help us manage these advanced cases in a better objective manner.</p>","PeriodicalId":17301,"journal":{"name":"Journal of the Egyptian National Cancer Institute","volume":"37 1","pages":"17"},"PeriodicalIF":2.1000,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Egyptian National Cancer Institute","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s43046-025-00256-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The nodal positivity in advanced ovarian cancers is approximately 68-70% histopathologically. Even after neoadjuvant chemotherapy (NACT) chance of nodal positivity is around 50-80%. In the prevailing literature, the nodal burden is a neglected entity in both assessment and documentation and complete clearance during the CRS. We aim to highlight the importance of nodal dissection and propose a Nodal Cancer Index (NCI) like PCI for ovarian cancers based on our experience of 105 cases.

Materials and methods: We included 105 patients with advanced ovarian cancers who underwent CRS. Retroperitoneal lymph nodes and bilateral pelvic lymph node dissection were routinely done in all the cases. For Nodal Cancer Index calculation, the abdomen is divided into 13 zones, zones 1-6 for retroperitoneum, zones 1-6 for Pelvic nodes, and zone 0 for extra-abdominal nodes. Furthermore, a Nodal size score ranging from 1 to 3 has been proposed so that the Nodal Cancer Index ranges from 13 to 39.

Results: The median age of the patients was 51 years (range 19-71) and the most significant patients were in stage III (65.7%), and 34.3% had stage IV disease at presentation. The lymph nodes were found to be positive in 62 patients (59%), and the positivity rate was higher in patients who underwent upfront surgery 36 (58.1%) as compared to 26 (41.9%) in those who received NACT. The majority of the patients (56.6%) had positive lymph nodes in both the pelvic and retroperitoneal groups, whereas 19.3% had only pelvic nodes positive, and 24.2% had only retroperitoneal nodes positive. The probability of overall survival at 5 years in our patients was 48.9% (95% CI = 35.5-61).

Conclusion: The results of our analytic observation confirm that systemic lymphadenectomy of all 13 zones proposed by our study should be an integral part of optimal CRS in the advanced carcinoma ovary and this will help us manage these advanced cases in a better objective manner.

建议的卵巢癌结节癌指数(NCI)。
导言:晚期卵巢癌的淋巴结阳性在病理组织学上约为68-70%。即使在新辅助化疗(NACT)后,淋巴结阳性的机会也在50-80%左右。在主流文献中,淋巴结负担在CRS期间的评估和记录以及完全清除中都是一个被忽视的实体。我们的目的是强调淋巴结清扫的重要性,并根据我们105例卵巢癌的经验提出一个类似于PCI的淋巴结癌指数(NCI)。材料和方法:我们纳入了105例接受CRS的晚期卵巢癌患者。所有病例均常规行腹膜后淋巴结及双侧盆腔淋巴结清扫。计算结癌指数时,腹部分为13个区,腹膜后1-6区,盆腔淋巴结1-6区,腹外淋巴结0区。此外,还提出了淋巴结大小评分范围为1 - 3,因此淋巴结癌指数范围为13 - 39。结果:患者的中位年龄为51岁(范围19-71岁),最显著的患者为III期(65.7%),34.3%的患者就诊时为IV期。62例(59%)患者的淋巴结呈阳性,前期手术患者的阳性率36例(58.1%)高于NACT患者的阳性率26例(41.9%)。盆腔和腹膜后淋巴结均为阳性的患者占56.6%,仅盆腔淋巴结为19.3%,仅腹膜后淋巴结为24.2%。患者5年总生存率为48.9% (95% CI = 35.5-61)。结论:我们的分析观察结果证实,我们提出的全部13区全身淋巴结切除术应该是晚期卵巢癌最佳CRS的一个组成部分,这将有助于我们更好地客观地管理这些晚期病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
46
审稿时长
11 weeks
期刊介绍: As the official publication of the National Cancer Institute, Cairo University, the Journal of the Egyptian National Cancer Institute (JENCI) is an open access peer-reviewed journal that publishes on the latest innovations in oncology and thereby, providing academics and clinicians a leading research platform. JENCI welcomes submissions pertaining to all fields of basic, applied and clinical cancer research. Main topics of interest include: local and systemic anticancer therapy (with specific interest on applied cancer research from developing countries); experimental oncology; early cancer detection; randomized trials (including negatives ones); and key emerging fields of personalized medicine, such as molecular pathology, bioinformatics, and biotechnologies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信